Access the full text.
Sign up today, get DeepDyve free for 14 days.
Shih-Ya Ma, L. See, C. Lai, H. Chou, C. Tsai, K. Ng, S. Hsueh, Wuu-Jyh Lin, Jenn-Tzong Chen, T. Yen (2003)
Delayed 18F-FDG PET for Detection of Paraaortic Lymph Node Metastases in Cervical Cancer PatientsThe Journal of Nuclear Medicine, 44
F. Tixier, C. Rest, M. Hatt, N. Albarghach, O. Pradier, J. Metges, L. Corcos, D. Visvikis (2011)
Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal CancerThe Journal of Nuclear Medicine, 52
Danny Costantini, R. Vali, J. Chan, Susan McQuattie, M. Charron (2013)
Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.AJR. American journal of roentgenology, 200 2
J. Huh (2012)
Epidemiologic overview of malignant lymphomaThe Korean Journal of Hematology, 47
Rakesh Kumar, V. Loving, A. Chauhan, H. Zhuang, S. Mitchell, A. Alavi (2005)
Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 11
Do-Hoon Kim, Ji-hoon Jung, S. Son, Choon-Young Kim, C. Hong, Jong-Ryool Oh, S. Jeong, Sang-Woo Lee, Jaetae Lee, B. Ahn (2015)
Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung CancerClinical Nuclear Medicine, 40
A. Zytoon, Koji Murakami, M. El-kholy, E. El-Shorbagy (2008)
Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.Clinical radiology, 63 11
T. Higashi, T. Saga, Y. Nakamoto, T. Ishimori, M. Mamede, M. Wada, R. Doi, R. Hosotani, M. Imamura, J. Konishi (2002)
Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 43 2
W. Chan, S. Ramsay, E. Szeto, J. Freund, J. Pohlen, L. Tarlinton, A. Young, Adam Hickey, R. Dura (2011)
Dual‐time‐point 18F‐FDG‐PET/CT imaging in the assessment of suspected malignancyJournal of Medical Imaging and Radiation Oncology, 55
R Siegel, D Naishadham, A Jemal (2013)
Cancer statistics, 2013. CA: a cancer journal for cliniciansCA Cancer J Clin, 63
W. Weber (2007)
18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?Journal of Nuclear Medicine, 48
A. Matthies, M. Hickeson, A. Cuchiara, A. Alavi (2002)
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 43 7
Haiping Liu, Ping Chen, K. Wroblewski, P. Hou, Chenpeng Zhang, Yulei Jiang, Y. Pu (2015)
Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake timesNuclear Medicine Communications, 37
Zheng Zhou, L. Sehn, A. Rademaker, L. Gordon, A. LaCasce, Allison Crosby‐Thompson, A. Vanderplas, A. Zelenetz, G. Abel, M. Rodriguez, A. Nademanee, M. Kaminski, M. Czuczman, M. Millenson, J. Niland, R. Gascoyne, J. Connors, J. Friedberg, J. Winter (2014)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood, 123 6
M. Ziepert, D. Hasenclever, E. Kuhnt, B. Glass, N. Schmitz, M. Pfreundschuh, M. Loeffler (2010)
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 14
O. Hoekstra, G. Ossenkoppele, R. Golding, A. Lingen, G. Visser, G. Teule, P. Huijgens (1993)
Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 34 10
M. Nakayama, A. Okizaki, S. Ishitoya, Miki Sakaguchi, J. Sato, T. Aburano (2012)
Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesionsAnnals of Nuclear Medicine, 27
L. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, Paul Hoskins, R. Klasa, K. Savage, T. Shenkier, J. Sutherland, R. Gascoyne, J. Connors (2007)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.Blood, 109 5
C. Bodet-Milin, T. Eugène, T. Gastinne, C. Bailly, S. Gouill, B. Dupas, F. Kraeber-Bodéré (2013)
The role of FDG-PET scanning in assessing lymphoma in 2012.Diagnostic and interventional imaging, 94 2
B. Sanghera, W. Wong, M. Lodge, S. Hain, D. Stott, J. Lowe, C. Lemon, K. Goodchild, M. Saunders (2005)
Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancerNuclear Medicine Communications, 26
G. Salles, D. Jong, W. Xie, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, M. Calaminici, B. Sander, C. Thorns, E. Campo, T. Molina, Abigail Lee, M. Pfreundschuh, S. Horning, A. Lister, L. Sehn, J. Raemaekers, A. Hagenbeek, R. Gascoyne, E. Weller (2011)
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.Blood, 117 26
A. Surbone, D. Longo, V. Devita, D. Ihde, P. Duffey, E. Jaffe, D. Solomon, S. Hubbard, R. Young (1988)
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 12
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
Y. Xiu, C. Bhutani, T. Dhurairaj, J. Yu, S. Dadparvar, Swapna Reddy, Rakesh Kumar, Hua Yang, A. Alavi, H. Zhuang (2007)
Dual-Time Point FDG PET Imaging in the Evaluation of Pulmonary Nodules With Minimally Increased Metabolic ActivityClinical Nuclear Medicine, 32
T Kitao, K Hirata, K Shima, N Tamaki (2014)
Influence of uptake time on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on FDG PET in non-small cell lung cancer (NSCLC)Soc Nuclear Med, 55
D. Fuster, S. Lafuente, X. Setoain, I. Navales, A. Perissinotti, J. Pavía, P. Paredes, F. Lomeña, F. Pons (2012)
Dual-time point images of the liver with 18F-FDG PET/CT in suspected recurrence from colorectal cancerRevista Espanola De Medicina Nuclear, 31
D. Uesaka, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, Y. Fujibayashi, H. Okazawa (2008)
Evaluation of Dual–Time-Point 18F-FDG PET for Staging in Patients with Lung CancerJournal of Nuclear Medicine, 49
Fanny Orlhac, M. Soussan, J. Maisonobe, C. Garcia, B. Vanderlinden, I. Buvat (2014)
Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion GlycolysisThe Journal of Nuclear Medicine, 55
C. Haioun, E. Itti, A. Rahmouni, P. Brice, J. Rain, K. Belhadj, P. Gaulard, L. Garderet, É. Lepage, F. Reyes, M. Meignan (2005)
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.Blood, 106 4
B. Cheson, S. Horning, B. Coiffier, M. Shipp, R. Fisher, J. Connors, T. Lister, J. Vose, A. Grillo‐López, A. Hagenbeek, F. Cabanillas, Donald Klippensten, W. Hiddemann, R. Castellino, N. Harris, J. Armitage, W. Carter, R. Hoppe, G. Canellos (1999)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 4
Tomoka Kitao, K. Hirata, K. Shima, N. Tamaki (2014)
Influence of uptake time on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on FDG PET in non-small cell lung cancer (NSCLC)The Journal of Nuclear Medicine, 55
N. Mikhaeel, M. Hutchings, P. Fields, M. O'Doherty, A. Timothy (2005)
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology, 16 9
R. Siegel, D. Naishadham, A. Jemal (2013)
Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 63
DL Costantini, R Vali, J Chan, S McQuattie, M Charron (2013)
Dual–time-point FDG PET/CT for the evaluation of pediatric tumorsAm J Roentgenol, 200
Takayoshi Shinya, S. Fujii, S. Asakura, Toshitaka Taniguchi, Kotaro Yoshio, Aierken Alafate, Shuhei Sato, T. Yoshino, S. Kanazawa (2012)
Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphomaAnnals of Nuclear Medicine, 26
O. Hoekstra, A. Lingen, G. Ossenkoppele, R. Golding, G. Teule (1993)
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomographyEuropean Journal of Nuclear Medicine, 20
R. Wilder, Maria Rodriguez, L. Medeiros, S. Tucker, C. Ha, J. Romaguera, B. Pro, M. Hess, F. Cabanillas, J. Cox (2002)
International prognostic index‐based outcomes for diffuse large B‐cell lymphomasCancer, 94
Nucl Med Mol Imaging (2017) 51:323–330 DOI 10.1007/s13139-017-0480-y ISSN (print) 1869-3482 ORIGINAL ARTICLE ISSN (online) 1869-3474 Relationship Between Dual Time Point FDG PET/CTand Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study 1 2 Do Hyoung Lim & Jai Hyuen Lee Received: 12 December 2016 /Revised: 20 February 2017 /Accepted: 21 March 2017 /Published online: 10 April 2017 Korean Society of Nuclear Medicine 2017 Abstract than the low risk group (p = 0.004). In the case of revised IPI, Purpose This study investigated the correlative relationship the RI of the low risk group were significantly lower than max between metabolic parameters estimated from dual time point the intermediate and high risk groups, respectively (p < 0.01). 18 18 2-deoxy-2-[ F] fluoro-D-glucose ( F-FDG) positron emis- The MVDIs of the best outcome group were decreased in sion tomography/computerized tomography (PET/CT) and comparison to the moderate outcome group (p = 0.029). the clinical tools predicting the outcome of a lymphoma. We There was a significant negative correlative relationship be- also measured metabolic and volumetric alterations between tween RI and MVDI, and the inclinations for decreased max early and delayed F-FDG PET/CT in patients with high MVDIs were slightly
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Apr 10, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.